扶正化瘀胶囊联合异甘草酸镁治疗HBV感染失代偿期肝硬化患者的疗效分析

Efficacy Analysis of Fuzheng Huayu Capsule Combined with Magnesium Isoglycyrrhizinate in Treating Patients with HBV Related Decompensated Liver Cirrhosis

目的 探讨扶正化瘀胶囊联合异甘草酸镁治疗丙型肝,炎病毒(HBV)感染引起的失代偿期肝硬化患者的临床效果,并分析其对炎症因子和肝纤维化指标,的影响。方法 选取HBV感染失代偿期肝硬化患者100例随机分为对照组和观察组。对照组给予异甘草酸镁治疗观察组在此基础上联合应用扶正化瘀胶囊两组均治疗2周。比较两组患者的临床疗效、肝功能指标(丙氨酸氨基转移酶ALT、天冬氨酸氨基转移酶AST、白蛋白ALB、总胆红素TBIL)、肝纤维化指标(透明质酸,HA、层粘连蛋白LN、Ⅲ型;前胶原PCⅢ、IV型胶原,CIV)及炎;症因子(白细胞介素-6IL-6、C反;应蛋白CRP、肿瘤坏死因子-αTNF-α)水平。结果 与对照组相比观察组临床总有效率更高ALT、AST、TBIL更低ALB更高HA、LN、PCⅢ、CIV水平更低IL-6、CRP、TNF-α水平也更低。两组不良反应发生率无统计学差异。结论 扶正化瘀胶囊与异甘草酸镁的联合治疗显著提升了HBV感染导致的失代偿期肝硬化患者的治疗效果,同时改善了肝功能和降低了炎症因子及肝纤维化的相关指标。

Objective To investigate the clinical efficacy and effects of Fuzheng Huayu Capsule(FZHYC)combined with magnesium isoglycyrrhizinate on inflammatory factors and liver fibrosis indicators in patients with HBV-related decompensated liver cirrhosis.Methods 100 patients with HBV-related decompensated liver cirrhosis were randomly divided into control group and observation group.The control group was treated with magnesium isoglycyrrhizinate,while the observation group received additional FZHYC.Both groups were treated for 2 weeks.The clinical efficacy,liver function indexes(ALT,AST,ALB,TBIL),liver fibrosis indicators(HA,LN,PCIII,CIV),and inflammatory factors(IL-6,CRP,TNF-α)were compared between the two groups.Results Compared with the control group,the observation group had higher total effective rate,lower ALT,AST,TBIL,and higher ALB levels.HA,LN,PCIII,CIV levels were also lower in the observation group.Additionally,IL-6,CRP,TNF-αlevels were lower in the observation group.There was no significant difference in adverse reaction rate between the two groups.Conclusion FZHYC combined with magnesium isoglycyrrhizinate can improve the clinical efficacy,liver function,inflammation status,and alleviate liver fibrosis in patients with HBV-related decompensated cirrhosis,with good safety.